If you run third-party radiology AI through Blackford, the platform routing those algorithms into your PACS has changed hands twice since 2023, and its new owner promises only continued service to existing customers. Sopris Capital had completed its purchase of Blackford Analysis from Bayer, AuntMinnie reported on October 9, 2026, did not disclose the price, and plans to merge Blackford into its portfolio company Azra AI within weeks. Nothing public covers pricing, the business associate agreement, or the contracts with the 45-plus AI vendors whose apps run on the platform. That leaves a short window to get those answers on paper before the integration starts changing the product.
What Sopris Actually Bought
Sopris bought an orchestration layer: the software that sits between your imaging systems and a catalog of other companies' AI apps. Imaging AI orchestration means one platform receives studies from PACS, RIS or a vendor-neutral archive, sends each to the right algorithm, and returns the result to the radiologist's worklist. You contract once with the platform instead of once per algorithm.
According to AuntMinnie's report on the closing, Blackford gives access to more than 130 AI applications from more than 45 vendors. It stays a separate legal entity with operations in Scotland and the U.S., and Sopris says it will keep serving its equipment-maker partners and health system customers. Abinav Sankar, managing partner at Sopris, told the outlet that "Blackford gives us a critical foothold at the very beginning of that journey," meaning the patient's path from first scan onward.
Blackford's own site describes deployment "on-premise, in the cloud or via a hybrid model," sells a "Core Subscription" covering the platform and its AI portfolio, and lists GE HealthCare, Philips, Intelerad, Merative and Mach7 among the logos under "Trusted by Leading Healthcare Companies." It does not say what each of those relationships is. One relationship is documented: in October 2024 GE HealthCare integrated the Blackford Platform into True PACS and Centricity PACS. So some hospitals use Blackford without having signed with Blackford at all.
Why Azra AI Wants an Imaging Platform
Azra wants Blackford's detections feeding its follow-up queues. Azra, based in Nashville, describes itself as an overlay on the EHR with bidirectional integration, where the EHR stays the system of record and Azra acts as the patient management layer. It sells incidental findings management, oncology navigation, clinical trial matching and cancer registry automation, and claims deployment at more than 1,500 sites. It names no customers.
The two companies were already partners. Their August 5, 2026 announcement paired Blackford's 130-plus imaging apps with Azra's navigation tools. Azra CEO John Marshall said, "A finding that is detected but not followed up on is not a win for the patient." A Nelson Advisors write-up of the deal describes the acquisition as formalising that commercial relationship, says Blackford managing director James Holroyd will continue to lead imaging operations, and says existing commercial distribution agreements "remain fully operational." That piece is an adviser's commentary, not a Sopris filing.
The strategic logic holds up. A nodule flagged by an algorithm only helps the patient if someone books the follow-up CT, and Azra sells exactly that workflow. The risk for you is roadmap gravity. An owner whose money comes from oncology navigation will fund the apps that feed its queues first. Musculoskeletal, neurology and operational apps that create no follow-up work may get less attention over time.
The Catalog Has Been Shrinking
Blackford's vendor count dropped between the two ownership changes. When Bayer pulled out in September 2025, AuntMinnieEurope reported that the platform offered more than 150 third-party AI applications from more than 60 developers. At closing this month the figure is more than 130 apps from more than 45 vendors. Blackford's own site shows both versions, "130+ contracted AI applications across 50+ partner vendors" in one place and "150+ contracted AI solutions across 60+ partner vendors" in another.
These are "more than" numbers from different sources, so the exact loss is uncertain. The direction is consistent, though: fewer vendors are listed now than a year ago. Any app you bought through the platform from a vendor that dropped off is a contract you should already know about. If you do not know about it, ask.
The economics explain the churn. In the same AuntMinnieEurope piece, an unnamed analyst said the model needs heavy usage to justify a 30% platform fee. Umar Ahmed of Signify Research said "Adoption has been slower than expected, reimbursement remains narrow in scope, and IT integration is a hurdle for many hospitals," and estimated that nearly 10% of current spend in the AI radiology platform market disappeared with Blackford and Bayer's Calantic. A vendor selling little through a platform has little reason to stay on it.
What Happened the Last Time Blackford Changed Hands
The last owner fulfilled contracts and then left the business. Bayer announced the Blackford acquisition in January 2023 to anchor Calantic, its imaging AI platform, which grew out of a 2020 licensing deal with Blackford. Pharmaceutical division president Stefan Oelrich said the deal "secures Bayer an excellent position."
Thirty-two months later, Bayer told AuntMinnieEurope it would "deprioritize its digital platform business, which includes Blackford, and will discontinue offerings and services." It said existing contracts would be fulfilled, that a core team would support the platform through the transition, and that it was "committed to managing our obligations to customers, partners, and employees." It declined to discuss a sale at the time. Thirteen months later, Sopris closed on the company.
That is the realistic range for a continuity promise. Bayer kept its word on existing contracts. It made no promise about renewals or roadmap, and customers who renewed during the wind-down were buying from an owner that had already announced it was leaving. "Keeps serving existing customers" from Sopris carries the same limits. It covers today's contract and says nothing about the next one.
We have seen the same pattern across this year's deals: Mark43's one-sentence cross-vendor pledge, Stilla's continuity promise before Meta folded it into WhatsApp, and Progress taking Domo's customers through an asset purchase. In each case, the only commitment a customer could enforce was the one already written into its contract.
The BAA Question Nobody Has Answered
Your business associate agreement with Blackford is where an owner change creates real exposure. HIPAA requires the BAA to make the vendor ensure that any subcontractors that create, receive, maintain, or transmit protected health information agree to the same restrictions. It also requires the vendor to return or destroy PHI at termination where feasible, and it must authorize you to terminate if the vendor breaches a material term.
Blackford sends your studies to dozens of AI vendors. Each one that touches PHI is a subcontractor under that rule, and the chain of agreements runs through Blackford. A merger with Azra adds a new question: will imaging data or algorithm outputs move into Azra's patient management platform, and under which agreement? Azra's model depends on reading clinical data across the EHR. Combining that with imaging findings is the whole point of the deal. Your existing BAA almost certainly did not contemplate it.
We covered this same issue when MRO bought Vyne Medical: the security attestation belonged to the target, and nobody had said who would run its controls after closing. The ambient scribe buyer's guide set out the BAA terms worth negotiating for any clinical AI vendor. Both apply here.
Who Should Act and What to Ask
The teams that need to act are radiology informatics, the CMIO's office and health system procurement, in roughly that order. If you bought Blackford through GE HealthCare or another equipment partner, the conversation starts with that partner, because your contract is with them.
This Week:
- Pull every contract that touches Blackford: the direct subscription, any OEM bundle, and any per-app agreement. Note the change-of-control, assignment and termination-for-convenience language in each. Our guide to AI vendor exit clauses lists what standard terms usually give you, often between 0 and 90 days.
- Export the list of apps actually running in production from the Blackford console, with volumes for the last 90 days. Match each to the vendor list you were sold. Any gap is a vendor that already left.
- Email your Blackford account contact and ask in writing whether pricing, the BAA and the subprocessor list stay unchanged through your current term.
This Month:
- Ask Sopris or Azra for a written statement of whether imaging data, DICOM metadata or algorithm outputs will flow into Azra's platform, and under which BAA. Do not accept a verbal answer.
- For each clinical app you depend on, ask the underlying AI vendor whether its agreement with Blackford survives the Azra merger, and whether it will contract with you directly if it does not.
- Rerun local validation on the two or three apps whose outputs drive clinical action. The i3LUNG external validation study is a reminder that imaging models can underperform once they leave their training site, and a new owner is a sensible moment to recheck.
Before Renewal:
- Add a change-of-control clause that lets you terminate without penalty within 180 days of any further sale or merger, with a funded data return.
- Price a fallback. Get one quote for direct contracts with your top three app vendors, and one from an alternative orchestration platform or your PACS vendor's native option.
The Bottom Line
Radiology AI platforms were sold on the promise that one contract would cover dozens of algorithms. That holds only while the platform owner wants to stay in the business. Blackford has now been owned by a university spinout, a pharmaceutical company that left within three years, and a growth equity firm merging it into an oncology navigation company. Both corporate owners said existing customers would be served, and neither published terms beyond that.
The combination with Azra may well be good for patients, since detection and follow-up belong in the same workflow. For your contract, the useful question is narrower: which of the apps you depend on will still be on the platform at renewal, and who will hold your imaging data when you get there. Send the written questions to Blackford this week, before the merger closes.
Continue Reading
- AI Vendor Exit Clauses: Standard Terms Give 0 to 90 Days to Get Out
- MRO Bought Vyne Medical. Ask Who Runs Trace's HITRUST Controls.
- Best Ambient AI Scribes Save 16 Minutes a Day, Not an Hour
- Lung Cancer AI: Chart Data Held Up. Scans and Slides Didn't.
- Mark43 Buys ForceMetrics With a One-Sentence Cross-Vendor Pledge
- Progress Took Domo's 2,400 Customers but Not Its Founder